"In May 2003, Easton led a $55.3 million financing for Acorda Therapeutics,
one of the top three private biotechnology financings to date in 2003. Easton's ability to lead
such a significant round, particularly in a challenging financial environment, is a testament to
its capabilities and excellence. Acorda's management and Board were thoroughly impressed by the
acumen and performance of the people at Easton. They comprise a rare mix of expertise in finance,
life sciences, business development and value creation, together with meticulous attention to detail
and passionate commitment. We are especially pleased that John Friedman has joined our Board of
Directors, where we expect his insights to contribute substantially to Acorda's future successes."
Ron Cohen
Founder, President, and CEO, Acorda Therapeutics
Acorda Therapeutics, Inc.
Acorda Therapeutics (NASD:ACOR) is a biotechnology company developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in late stage development for MS. Acorda also has a marketed product, Zanaflex (R) for spasticity, a common problem in patienst with SCI. The company's technology platform includes two remyelinating agents in preclinical development for MS. EHCP led the company's financing round in 2002. Other prominent new investors included ABN AMRO Capital, Cross Atlantic Partners, JP Morgan Fleming Asset Management, and Techno Venture Management. Acorda had a successful initial public offering in February 2006. In September 2006, the company announced positive results from a Phase 3 trial of Fampridine for MS. Between November 2006 and February 2007, Easton
sold its stake in Acorda providing Easton with proceeds 2.5x its initial
cost.